For information about COVID-19, including symptoms and prevention, please read our COVID-19 patient guide. Please also consider supporting Weill Cornell Medicine’s efforts against the pandemic.
Jump To

    Testing Portfolio

    What is Genomic Testing?

    Genomic testing is a process by which clinicians study the activity and interaction of genes within the human body. The Weill Cornell Medicine Clinical Genomics Laboratory facilitates genomic testing assessments of mutations in roughly 22,000 different human genes. These assessments provide clinically actionable diagnoses for personalized patient care. Our highly trained professional staff members use genomic tests to identify alterations in genes that cause cancer to grow and spread within the body, determine the genetic drivers of these mutations and provide insights for disease treatment.

    How Genomic Tests Work

    The genomic testing process is designed to provide high-quality information for patients as quickly and accurately as possible. We integrate the latest sequencing technology with the insights of a highly professional and skilled team of pathologists, computational biologists and scientists to help clinicians and translational researchers identify the best possible treatment decisions for their patients. Our EXaCT-1 clinical genomic test, the first whole-exome sequencing, clinical cancer test approved by the state of New York, allows for examination of the genomic mutations of all genes in each patient’s cancer cells and generally requires only three-four weeks to deliver results after samples arrive in our laboratory.

    Available Tests

    Scroll to the right to read this table on a mobile device.

    Test Name Indication Type # of Genes Turnaround Time Ordering Instructions
    EXaCT-1 (Whole-Exome Sequencing) Comprehensive profile of all genes within cancer cells – EXaCT-1 facilitates a more complete understanding of a patient’s cancer through evaluation of an entire tumor exome. Solid tumor and hematologic malignancies ~22,000 3-4 weeks
    50-Gene Mutations in lung, colon, rectum, thyroid, brain and skin cancer Solid tumors 50 7-14 days
    My Heme Panel Mutation status of recurrently mutated genes in patients with myeloid neoplasms Hematopoietic myeloid neoplasms 45 5-10 days
    Oncomine Clinically significant somatic mutations Solid neoplasms 143, including RNA fusions 10-14 days

    There are currently no Genomic Tests in that category.